Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recurrent cutaneous leiomyosarcoma.

R A Wascher1, M Y Lee

  • 1Department of Surgery, Tripler Army Medical Center, Honolulu, HI 96859.

Cancer
|July 15, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for Light Pseudoscalar Bosons, Pair-Produced in Higgs Boson Decays in the Four-Electron Final State in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

First Evidence for Mixing-Induced CP Violation in B_{s}^{0}→J/ψϕ(1020) Decays in pp Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

Observation of Suppressed Charged-Particle Production in Ultrarelativistic Oxygen-Oxygen Collisions.

Physical review letters·2026
Same author

Measurement of D^{0} Meson Photoproduction in Ultraperipheral Heavy Ion Collisions.

Physical review letters·2026
Same author

Observation of tWZ Production at the CMS Experiment.

Physical review letters·2026
Same author

First Exclusive Reconstruction of the B^{*+}, B^{*0}, and B_{s}^{*0} Mesons and Precise Measurement of Their Masses.

Physical review letters·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
Same journal

Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

Cancer·2026
Same journal

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
See all related articles

Wide local excision is the recommended treatment for superficial leiomyosarcoma. This rare cancer, including cutaneous leiomyosarcoma, has a good prognosis with this surgical approach.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Dermatopathology

Background:

  • Soft tissue sarcomas are rare, accounting for about 0.7% of all malignant neoplasms.
  • Superficial leiomyosarcoma, a rare malignant lesion, comprises 4.0-6.5% of soft tissue sarcomas.
  • Fewer than 125 cases of cutaneous and subcutaneous leiomyosarcoma have been reported.

Observation:

  • A 70-year-old Japanese man with recurrent cutaneous leiomyosarcoma was treated with wide local excision.
  • The patient remained recurrence-free one year post-surgery for a second recurrence.
  • Superficial leiomyosarcoma can be classified into cutaneous and subcutaneous types.

Findings:

  • Wide local excision is the primary treatment for superficial leiomyosarcoma.
  • Cutaneous leiomyosarcoma is associated with local recurrence only.

Related Experiment Videos

  • Subcutaneous leiomyosarcoma has a 30-60% metastasis rate and 30-40% mortality.

    • Implications:

    • Wide local excision offers a favorable outcome for superficial leiomyosarcoma, particularly the cutaneous type.
    • Distinguishing between cutaneous and subcutaneous leiomyosarcoma is crucial for prognosis and treatment planning.
    • Further research into metastatic patterns and treatment optimization for subcutaneous leiomyosarcoma is warranted.